Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-DP study
2023-505571-78-00Phase 4Authorised
- Sponsor
- Instituto de Investigación Sanitaria Hospital Clínico San Carlos
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in heart failure (HF) and chronic kidney disease (CKD), sponsored by Instituto de Investigación Sanitaria Hospital Clínico San Carlos. Primary endpoint: Change in combined 24-hour natriuresis and daily peritoneal dialytic sodium removal. Planned start Sep 2023; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-505571-78-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505571-78-00.